In this trial, BBI608 did not improve overall survival (OS) or progression-free survival (PFS) in unselected patients with advanced CRC but did improve OS in pSTAT3-positive patients compared to the placebo group, suggesting that STAT3 may be an important target for CRC treatment [131,132]. This evidence concerns the gene STAT3 and colorectal carcinoma.